Karius will expand access to its proprietary microbial cell-free DNA technology to help doctors diagnose infectious diseases, broaden clinical development, and accelerate technology innovation REDWOOD CITY, Calif., February 24, 2020-- Karius, the world leader in liquid biopsy for infectious diseases, secured $165 million in a new funding round led by SoftBank Vision Fund 21, with additional participation from General Catalyst, HBM Healthcare Investments, and existing investors Khosla Ventures and LightSpeed Venture Partners. Karius pioneered the discovery and application of microbial cell-free DNA, enabling non-invasive detection of pathogens throughout the body with its Karius® Test.